Transdermal rivastigmine for dementia: transdermal formulation may reduce side effects, making optimal dosing easier - Document - Gale Academic OneFile
![PDF) Safety and tolerability of transdermal and oral rivastigmine in Alzheimer's disease and Parkinson's disease dementia PDF) Safety and tolerability of transdermal and oral rivastigmine in Alzheimer's disease and Parkinson's disease dementia](https://i1.rgstatic.net/publication/40728794_Safety_and_tolerability_of_transdermal_and_oral_rivastigmine_in_Alzheimer's_disease_and_Parkinson's_disease_dementia/links/0fcfd50acade2d060f000000/largepreview.png)
PDF) Safety and tolerability of transdermal and oral rivastigmine in Alzheimer's disease and Parkinson's disease dementia
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT <invented name> 4.6 mg/24 h transdermal patch <inve
![Rivastigmine (Exelon) Patch May Complicate Use of Neuromuscular Blocking Drugs - Anesthesia Patient Safety Foundation Rivastigmine (Exelon) Patch May Complicate Use of Neuromuscular Blocking Drugs - Anesthesia Patient Safety Foundation](https://www.apsf.org/wp-content/uploads/newsletters/2014/winter/image/exelon_plaster3_opt.jpeg)